GlassScriptPhysician profile
Mayling Chau
NPI 1558672634
$1,393.67
in general payments reported to CMS, 2019-2025
14 companies · $27.18 in 2025
The $27.18 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $453 · 2023: $473 · 2024: $303 · 2025: $27.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $697.38 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $239.44 | 2023 | Vemlidy, Epclusa |
| Redhill Biopharma INC. | $116.67 | 2022 | |
| Scynexis, INC. | $89.92 | 2022 | |
| Exact Sciences Corporation | $46.04 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $30.72 | 2022 | |
| Merck Sharp & Dohme LLC | $27.18 | 2025 | Gardasil 9, Vaqta, Capvaxive |
| Amarin Pharma, INC. | $25.00 | 2023 | |
| Alkermes, INC. | $23.31 | 2021 | |
| Sanofi Pasteur INC. | $22.07 | 2022 | |
| Qiagen, LLC | $19.64 | 2024 | |
| Dexcom, INC. | $19.30 | 2022 | |
| Abbvie INC. | $19.25 | 2023 | |
| Pfizer INC. | $17.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayling Chau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.